MA38472B1 - Composé peptidique - Google Patents
Composé peptidiqueInfo
- Publication number
- MA38472B1 MA38472B1 MA38472A MA38472A MA38472B1 MA 38472 B1 MA38472 B1 MA 38472B1 MA 38472 A MA38472 A MA 38472A MA 38472 A MA38472 A MA 38472A MA 38472 B1 MA38472 B1 MA 38472B1
- Authority
- MA
- Morocco
- Prior art keywords
- peptide compound
- relates
- medicament
- receptors
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un nouveau composé peptidique ayant pour effet d'activer les récepteurs au glp-1 et les récepteurs au gip, ainsi que l'utilisation dudit composé peptidique en tant que médicament. L'invention concerne, plus précisément, un peptide contenant une séquence partielle représentée par la formule (i), ou un sel de celui-ci et un médicament en contenant. P
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013111893 | 2013-05-28 | ||
| PCT/JP2014/002772 WO2014192284A1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38472A1 MA38472A1 (fr) | 2018-01-31 |
| MA38472B1 true MA38472B1 (fr) | 2018-09-28 |
Family
ID=50942304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38472A MA38472B1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10087229B2 (fr) |
| EP (1) | EP3004155B1 (fr) |
| JP (2) | JP6429799B2 (fr) |
| KR (1) | KR102229051B1 (fr) |
| CN (1) | CN105209485B (fr) |
| AP (1) | AP2015008781A0 (fr) |
| AR (1) | AR096440A1 (fr) |
| AU (1) | AU2014272500B2 (fr) |
| CA (1) | CA2908581C (fr) |
| CL (1) | CL2015003031A1 (fr) |
| CY (1) | CY1124790T1 (fr) |
| DK (1) | DK3004155T3 (fr) |
| DO (1) | DOP2015000261A (fr) |
| EA (2) | EA035813B1 (fr) |
| EC (1) | ECSP15044389A (fr) |
| ES (1) | ES2900744T3 (fr) |
| GE (1) | GEP201706762B (fr) |
| HR (1) | HRP20212014T1 (fr) |
| HU (1) | HUE057361T2 (fr) |
| IL (1) | IL242005B (fr) |
| LT (1) | LT3004155T (fr) |
| MA (1) | MA38472B1 (fr) |
| MX (2) | MX388826B (fr) |
| MY (1) | MY172744A (fr) |
| PE (1) | PE20151770A1 (fr) |
| PH (1) | PH12015502391B1 (fr) |
| PL (1) | PL3004155T3 (fr) |
| PT (1) | PT3004155T (fr) |
| SG (1) | SG11201507934PA (fr) |
| SI (1) | SI3004155T1 (fr) |
| TN (1) | TN2015000451A1 (fr) |
| TW (1) | TWI638831B (fr) |
| UA (1) | UA118558C2 (fr) |
| UY (1) | UY35589A (fr) |
| WO (1) | WO2014192284A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
| CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业（合肥）有限公司 | 一种多肽固相合成的监测方法 |
| CN109477094B (zh) * | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) * | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| WO2019140030A1 (fr) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| KR20200132852A (ko) | 2018-01-23 | 2020-11-25 | 길라 테라퓨틱스, 인코포레이티드 | 펩티드 yy 약학적 제형, 조성물, 및 방법 |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
| MA53378A (fr) * | 2018-07-23 | 2021-06-02 | Lilly Co Eli | Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète |
| CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
| EP3856339A1 (fr) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur gip et leurs utilisations |
| EP3856768A2 (fr) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur du gip et leurs utilisations |
| JP2022545200A (ja) * | 2019-08-19 | 2022-10-26 | イーライ リリー アンド カンパニー | インクレチン類似体を作製する方法 |
| CN114786706A (zh) | 2019-10-04 | 2022-07-22 | 韩美药品株式会社 | 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| AU2021241257A1 (en) * | 2020-03-25 | 2022-10-13 | Takeda Pharmaceutical Company Limited | QD dosing of GIP receptor agonist peptide compounds and uses thereof |
| JP7736315B2 (ja) * | 2020-03-31 | 2025-09-09 | アンタロス メディカル アクティエボラーグ | イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト |
| WO2022018185A1 (fr) | 2020-07-22 | 2022-01-27 | Novo Nordisk A/S | Co-agonistes de récepteurs de glp-1 et de gip |
| CA3184717A1 (fr) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonistes au niveau des recepteurs de glp-1 et de gip appropries pour une administration par voie orale |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022253202A1 (fr) | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN119522233A (zh) * | 2022-07-13 | 2025-02-25 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| CA3262093A1 (fr) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques |
| JP2025531200A (ja) | 2022-09-15 | 2025-09-19 | イーライ リリー アンド カンパニー | Ｇｉｐ及びｇｌｐ－１二重アゴニスト化合物 |
| AU2023415591A1 (en) | 2022-12-30 | 2025-08-14 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| WO2024165571A2 (fr) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4714434A1 (fr) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphère comprenant du tirzépatide, son procédé de préparation, et composition pharmaceutique la comprenant |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| TW202517291A (zh) | 2023-06-30 | 2025-05-01 | 丹麥商西蘭製藥公司 | 組合療法 |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025125576A2 (fr) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| WO2025133348A1 (fr) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4686757A1 (fr) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibiteurs d expression et/ou de fonction |
| WO2025140581A1 (fr) * | 2023-12-29 | 2025-07-03 | 杭州中美华东制药有限公司 | Procédé de synthèse en phase solide pour agoniste double de glp-1/gip |
| TW202535912A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物 |
| TW202535911A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的藥物組合物 |
| WO2025196502A1 (fr) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| DE69732572T2 (de) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | Verwendung von glp-1 peptiden |
| WO1999047161A1 (fr) | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Regulation de l'appetit chez les humains par un compose se liant a un recepteur de peptide de type glucagon |
| EP1100530B1 (fr) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In vitro stimulation de la proliferation des cellules de langerhans beta pancreatique |
| PL205713B1 (pl) | 1998-12-07 | 2010-05-31 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków |
| US20030157107A1 (en) | 2000-05-16 | 2003-08-21 | Kazumasa Miyawaki | Agents for preventing or ameliorating insulin resistance and/or obesity |
| MXPA04012497A (es) | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| CA2551039C (fr) | 2003-12-16 | 2013-01-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Analogues du glp-1 |
| WO2006049681A2 (fr) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Agonistes recepteur y2 neuropeptidiques selectifs |
| EP1853627A2 (fr) | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables |
| WO2006136374A2 (fr) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline |
| CA2657578A1 (fr) | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Procedes de traitement de l'obesite en utilisant des facteurs de satiete |
| WO2008021560A2 (fr) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Analogue du gip et polypeptides hybrides possédant des propriétés sélectives |
| PE20121528A1 (es) | 2006-09-13 | 2012-12-12 | Smithkline Beecham Corp | Metodos para administrar agentes hipoglucemiantes de larga duracion |
| EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
| EP2224945B1 (fr) | 2007-11-23 | 2012-05-16 | Michael Rothkopf | Procédés d'amplification de la résolution d'un diabète |
| BRPI0915282A2 (pt) * | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| BRPI0917580A2 (pt) | 2008-08-07 | 2016-10-11 | Ipsen Pharma Sas | composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| RU2012136450A (ru) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| WO2012167744A1 (fr) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation |
| WO2012168430A2 (fr) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
| US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| WO2013164483A1 (fr) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Composés agonistes doubles du gip-glp-1 et méthodes |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| JP6300239B2 (ja) | 2012-06-21 | 2018-03-28 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| WO2014096179A1 (fr) | 2012-12-19 | 2014-06-26 | Novo Nordisk A/S | Nouveaux agonistes des récepteurs à la glp-1 avec activité d'efflux du cholestérol |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| CA2902352A1 (fr) | 2013-03-14 | 2014-09-18 | Medimmune Limited | Co-agonistes pegyles du glucagon et de glp-1 pour le traitement de l'obesite |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 MX MX2019010531A patent/MX388826B/es unknown
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/fr not_active Ceased
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es active IP Right Grant
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 MX MX2015015464A patent/MX373436B/es active IP Right Grant
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/fr active Active
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active Active
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/fr active Active
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391B1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38472B1 (fr) | Composé peptidique | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA39246A1 (fr) | Composé hétérocyclique fusionné | |
| BR112017006253A2 (pt) | novos compostos | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| NZ707308A (en) | Malononitrile compounds for controlling animal pests | |
| MA39108A1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie sévère | |
| MX2015007568A (es) | Compuestos de malononitrilo para controlar plagas de animales. | |
| CL2018002422A1 (es) | Preparación que contiene agua de mar a la que se ha agregado un compuesto de potasio. | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| MA39756B1 (fr) | Nouveau sel de l'ivabradine et son procédé de préparation | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| AR112111A1 (es) | Tetrahidropiridopirazinas moduladoras de receptores gpr6 | |
| AR095761A1 (es) | Compuestos de dihidropirido pirimidina |